Clinical factors associated with fatigue over time in paediatric oncology patients receiving chemotherapy.
The purpose of this study was to investigate the relationships between clinical factors (including haemoglobin value, chemotherapeutic agents, and corticosteroid use) and changing patterns of fatigue before and for the next 10 days following the start of a new round of chemotherapy in children with cancer. A prospective longitudinal design was used to collect data from 48 paediatric oncology patients who were about to begin a new round of chemotherapy and their parents. Fatigue levels were assessed using multidomain questionnaires with three categories of patient self-report (including 'General Fatigue', 'Sleep/Rest Fatigue', and 'Cognitive Fatigue') and four categories of parent proxy-report (including 'Lack of Energy', 'Unable to Function', 'Altered Sleep', and 'Altered Mood'). The findings suggest that fatigue from both patient self-report and parent proxy-report changed significantly over time. The major findings from this study are that patients have more problems with fatigue in the first few days after the start of a cycle of chemotherapy. Corticosteroid use and haemoglobin value were associated with significant increases in fatigue that were sustained for several days and reached the highest level of fatigue at day 5 for those receiving concurrent steroids. The association of chemotherapeutic agents with fatigue varied between patient self-report and parent report, but the type of chemotherapeutic agents used was not associated with most changes in fatigue.
Yeh
C-H
CH
Graduate Institute of Nursing Science, Chang Gung University, Kwei-San, Tao-Yuen, Taiwan. cyeh@mail.cgu.edu.tw
Chiang
Y-C
YC
Lin
L
L
Yang
C-P
CP
Chien
L-C
LC
Weaver
M A
MA
Chuang
H-L
HL
D000293:Adolescent; D000740:Anemia / Q000097:blood / Q000150:complications; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002648:Child; D004359:Drug Therapy, Combination; D005221:Fatigue / Q000209:etiology*; D005260:Female; D005938:Glucocorticoids / Q000009:adverse effects; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008297:Male; D009369:Neoplasms / Q000150:complications*; D011446:Prospective Studies; D012307:Risk Factors
D000970:Antineoplastic Agents; D005938:Glucocorticoids; D006454:Hemoglobins